Tandem Meetings 2023 | Phase II study of EPd maintenance after second autologous transplant for multiple myeloma
Michael Slade, MD, Washington University School of Medicine, St Louis, MO, comments on the findings of a Phase II study of elotuzumab, pomalidomide and dexamethasone (EPd) maintenance after second autologous stem cell transplantation (autoSCT) in patients with relapsed multiple myeloma (NCT03030261). The primary endpoint of the study, one-year progression-free survival (PFS), was 72%, and the combination was well tolerated, with a low rate of treatment discontinuation due to toxicity. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
